# Royal Bank of Canada

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/royal-bank-of-canada
Canonical HTML page: https://getbiobrief.com/entity/royal-bank-of-canada

## Timeline

- **2026-Q3 (estimated)**: Clinical Catalyst — Anticipated data readouts for sevasemten in Becker Muscular Dystrophy trials.
- **2026-02-27**: 52-Week High — EWTX stock reaches a new yearly peak amid clinical pipeline optimism.
- **2026-02-17**: Analyst Upgrade — Wall Street Zen raises Edgewise Therapeutics to a 'Hold' rating.

## Recent coverage (2 stories)

### ResMed’s $270.64 Consensus Hides a 30% Spread in Analyst Targets
2026-07-10 14:14:59 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Full story: https://getbiobrief.com/story/resmed-analyst-divide-biotech-investment

### Edgewise Therapeutics Hits 52-Week High as Muscle Disease Pipeline Gains Momentum
2026-02-27 17:04:57 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Edgewise Therapeutics (NASDAQ: EWTX) has reached a new 52-week high, reflecting growing investor confidence in its clinical-stage pipeline for rare muscle and cardiac diseases. The surge follows recent analyst upgrades and positive sentiment surrounding its lead candidates, sevasemten and EDG-7500.
Full story: https://getbiobrief.com/story/edgewise-therapeutics-ewtx-52-week-high-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.